Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Following quite encouraging news from the laboratory on Monday, Amgen (NASDAQ: AMGN) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis.

TD Cowen analyst Yaron Werber reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s shares opened today at $278.85.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...